http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 03 Aug 2026 16:36:06 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/IPOs/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html <p>Apnimed, Inc. (Nasdaq: APMD), a Cambridge, Massachusetts-based clinical-stage pharmaceutical company, closed its initial public offering, raising $220.8 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses.</p> <p>The offering consisted of 13,800,000 shares of common stock priced at $16.00 per share, including 1,800,000 shares issued through the full exercise of the underwriters' overallotment option. All shares were offered by Apnimed. The stock began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol "APMD."</p> <p>BofA Securities, Evercore ISI, Cantor, and LifeSci Capital served as joint book-running managers for the offering.</p> <p>According to a press release, Apnimed http://www.streetinsider.com/IPOs/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html Mon, 03 Aug 2026 16:36:06 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537 http://www.streetinsider.com/IPOs/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html <p>Apnimed, Inc. (Nasdaq: APMD), a Cambridge, Massachusetts-based clinical-stage pharmaceutical company, closed its initial public offering, raising $220.8 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses.</p> <p>The offering consisted of 13,800,000 shares of common stock priced at $16.00 per share, including 1,800,000 shares issued through the full exercise of the underwriters' overallotment option. All shares were offered by Apnimed. The stock began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol "APMD."</p> <p>BofA Securities, Evercore ISI, Cantor, and LifeSci Capital served as joint book-running managers for the offering.</p> <p>According to a press release, Apnimed http://www.streetinsider.com/IPOs/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html Mon, 03 Aug 2026 16:36:06 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537 http://www.streetinsider.com/IPOs/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html <p>Apnimed, Inc. (Nasdaq: APMD), a Cambridge, Massachusetts-based clinical-stage pharmaceutical company, closed its initial public offering, raising $220.8 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses.</p> <p>The offering consisted of 13,800,000 shares of common stock priced at $16.00 per share, including 1,800,000 shares issued through the full exercise of the underwriters' overallotment option. All shares were offered by Apnimed. The stock began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol "APMD."</p> <p>BofA Securities, Evercore ISI, Cantor, and LifeSci Capital served as joint book-running managers for the offering.</p> <p>According to a press release, Apnimed http://www.streetinsider.com/IPOs/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html Mon, 03 Aug 2026 16:36:06 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537 http://www.streetinsider.com/IPOs/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html <p>Apnimed, Inc. (Nasdaq: APMD), a Cambridge, Massachusetts-based clinical-stage pharmaceutical company, closed its initial public offering, raising $220.8 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses.</p> <p>The offering consisted of 13,800,000 shares of common stock priced at $16.00 per share, including 1,800,000 shares issued through the full exercise of the underwriters' overallotment option. All shares were offered by Apnimed. The stock began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol "APMD."</p> <p>BofA Securities, Evercore ISI, Cantor, and LifeSci Capital served as joint book-running managers for the offering.</p> <p>According to a press release, Apnimed http://www.streetinsider.com/IPOs/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html Mon, 03 Aug 2026 16:36:06 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537 http://www.streetinsider.com/IPOs/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html <p>Apnimed, Inc. (Nasdaq: APMD), a Cambridge, Massachusetts-based clinical-stage pharmaceutical company, closed its initial public offering, raising $220.8 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses.</p> <p>The offering consisted of 13,800,000 shares of common stock priced at $16.00 per share, including 1,800,000 shares issued through the full exercise of the underwriters' overallotment option. All shares were offered by Apnimed. The stock began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol "APMD."</p> <p>BofA Securities, Evercore ISI, Cantor, and LifeSci Capital served as joint book-running managers for the offering.</p> <p>According to a press release, Apnimed http://www.streetinsider.com/IPOs/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html Mon, 03 Aug 2026 16:36:06 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537 http://www.streetinsider.com/IPOs/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html <p>Apnimed, Inc. (Nasdaq: APMD), a Cambridge, Massachusetts-based clinical-stage pharmaceutical company, closed its initial public offering, raising $220.8 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses.</p> <p>The offering consisted of 13,800,000 shares of common stock priced at $16.00 per share, including 1,800,000 shares issued through the full exercise of the underwriters' overallotment option. All shares were offered by Apnimed. The stock began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol "APMD."</p> <p>BofA Securities, Evercore ISI, Cantor, and LifeSci Capital served as joint book-running managers for the offering.</p> <p>According to a press release, Apnimed http://www.streetinsider.com/IPOs/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html Mon, 03 Aug 2026 16:36:06 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537 http://www.streetinsider.com/IPOs/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html <p>Apnimed, Inc. (Nasdaq: APMD), a Cambridge, Massachusetts-based clinical-stage pharmaceutical company, closed its initial public offering, raising $220.8 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses.</p> <p>The offering consisted of 13,800,000 shares of common stock priced at $16.00 per share, including 1,800,000 shares issued through the full exercise of the underwriters' overallotment option. All shares were offered by Apnimed. The stock began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol "APMD."</p> <p>BofA Securities, Evercore ISI, Cantor, and LifeSci Capital served as joint book-running managers for the offering.</p> <p>According to a press release, Apnimed http://www.streetinsider.com/IPOs/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html Mon, 03 Aug 2026 16:36:06 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537 http://www.streetinsider.com/IPOs/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html <p>Apnimed, Inc. (Nasdaq: APMD), a Cambridge, Massachusetts-based clinical-stage pharmaceutical company, closed its initial public offering, raising $220.8 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses.</p> <p>The offering consisted of 13,800,000 shares of common stock priced at $16.00 per share, including 1,800,000 shares issued through the full exercise of the underwriters' overallotment option. All shares were offered by Apnimed. The stock began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol "APMD."</p> <p>BofA Securities, Evercore ISI, Cantor, and LifeSci Capital served as joint book-running managers for the offering.</p> <p>According to a press release, Apnimed http://www.streetinsider.com/IPOs/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html Mon, 03 Aug 2026 16:36:06 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537 http://www.streetinsider.com/IPOs/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html <p>Apnimed, Inc. (Nasdaq: APMD), a Cambridge, Massachusetts-based clinical-stage pharmaceutical company, closed its initial public offering, raising $220.8 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses.</p> <p>The offering consisted of 13,800,000 shares of common stock priced at $16.00 per share, including 1,800,000 shares issued through the full exercise of the underwriters' overallotment option. All shares were offered by Apnimed. The stock began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol "APMD."</p> <p>BofA Securities, Evercore ISI, Cantor, and LifeSci Capital served as joint book-running managers for the offering.</p> <p>According to a press release, Apnimed http://www.streetinsider.com/IPOs/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html Mon, 03 Aug 2026 16:36:06 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537 http://www.streetinsider.com/Equity+Offerings/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html <p>Apnimed, Inc. (Nasdaq: APMD), a Cambridge, Massachusetts-based clinical-stage pharmaceutical company, closed its initial public offering, raising $220.8 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses.</p> <p>The offering consisted of 13,800,000 shares of common stock priced at $16.00 per share, including 1,800,000 shares issued through the full exercise of the underwriters' overallotment option. All shares were offered by Apnimed. The stock began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol "APMD."</p> <p>BofA Securities, Evercore ISI, Cantor, and LifeSci Capital served as joint book-running managers for the offering.</p> <p>According to a press release, Apnimed http://www.streetinsider.com/Equity+Offerings/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html Mon, 03 Aug 2026 16:36:06 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537 http://www.streetinsider.com/Equity+Offerings/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html <p>Apnimed, Inc. (Nasdaq: APMD), a Cambridge, Massachusetts-based clinical-stage pharmaceutical company, closed its initial public offering, raising $220.8 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses.</p> <p>The offering consisted of 13,800,000 shares of common stock priced at $16.00 per share, including 1,800,000 shares issued through the full exercise of the underwriters' overallotment option. All shares were offered by Apnimed. The stock began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol "APMD."</p> <p>BofA Securities, Evercore ISI, Cantor, and LifeSci Capital served as joint book-running managers for the offering.</p> <p>According to a press release, Apnimed http://www.streetinsider.com/Equity+Offerings/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html Mon, 03 Aug 2026 16:36:06 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537 http://www.streetinsider.com/Equity+Offerings/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html <p>Apnimed, Inc. (Nasdaq: APMD), a Cambridge, Massachusetts-based clinical-stage pharmaceutical company, closed its initial public offering, raising $220.8 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses.</p> <p>The offering consisted of 13,800,000 shares of common stock priced at $16.00 per share, including 1,800,000 shares issued through the full exercise of the underwriters' overallotment option. All shares were offered by Apnimed. The stock began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol "APMD."</p> <p>BofA Securities, Evercore ISI, Cantor, and LifeSci Capital served as joint book-running managers for the offering.</p> <p>According to a press release, Apnimed http://www.streetinsider.com/Equity+Offerings/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html Mon, 03 Aug 2026 16:36:06 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537 http://www.streetinsider.com/Equity+Offerings/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html <p>Apnimed, Inc. (Nasdaq: APMD), a Cambridge, Massachusetts-based clinical-stage pharmaceutical company, closed its initial public offering, raising $220.8 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses.</p> <p>The offering consisted of 13,800,000 shares of common stock priced at $16.00 per share, including 1,800,000 shares issued through the full exercise of the underwriters' overallotment option. All shares were offered by Apnimed. The stock began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol "APMD."</p> <p>BofA Securities, Evercore ISI, Cantor, and LifeSci Capital served as joint book-running managers for the offering.</p> <p>According to a press release, Apnimed http://www.streetinsider.com/Equity+Offerings/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html Mon, 03 Aug 2026 16:36:06 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537 http://www.streetinsider.com/Equity+Offerings/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html <p>Apnimed, Inc. (Nasdaq: APMD), a Cambridge, Massachusetts-based clinical-stage pharmaceutical company, closed its initial public offering, raising $220.8 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses.</p> <p>The offering consisted of 13,800,000 shares of common stock priced at $16.00 per share, including 1,800,000 shares issued through the full exercise of the underwriters' overallotment option. All shares were offered by Apnimed. The stock began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol "APMD."</p> <p>BofA Securities, Evercore ISI, Cantor, and LifeSci Capital served as joint book-running managers for the offering.</p> <p>According to a press release, Apnimed http://www.streetinsider.com/Equity+Offerings/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html Mon, 03 Aug 2026 16:36:06 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537 http://www.streetinsider.com/Equity+Offerings/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html <p>Apnimed, Inc. (Nasdaq: APMD), a Cambridge, Massachusetts-based clinical-stage pharmaceutical company, closed its initial public offering, raising $220.8 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses.</p> <p>The offering consisted of 13,800,000 shares of common stock priced at $16.00 per share, including 1,800,000 shares issued through the full exercise of the underwriters' overallotment option. All shares were offered by Apnimed. The stock began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol "APMD."</p> <p>BofA Securities, Evercore ISI, Cantor, and LifeSci Capital served as joint book-running managers for the offering.</p> <p>According to a press release, Apnimed http://www.streetinsider.com/Equity+Offerings/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html Mon, 03 Aug 2026 16:36:06 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537 http://www.streetinsider.com/Equity+Offerings/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html <p>Apnimed, Inc. (Nasdaq: APMD), a Cambridge, Massachusetts-based clinical-stage pharmaceutical company, closed its initial public offering, raising $220.8 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses.</p> <p>The offering consisted of 13,800,000 shares of common stock priced at $16.00 per share, including 1,800,000 shares issued through the full exercise of the underwriters' overallotment option. All shares were offered by Apnimed. The stock began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol "APMD."</p> <p>BofA Securities, Evercore ISI, Cantor, and LifeSci Capital served as joint book-running managers for the offering.</p> <p>According to a press release, Apnimed http://www.streetinsider.com/Equity+Offerings/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html Mon, 03 Aug 2026 16:36:06 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537 http://www.streetinsider.com/Equity+Offerings/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html <p>Apnimed, Inc. (Nasdaq: APMD), a Cambridge, Massachusetts-based clinical-stage pharmaceutical company, closed its initial public offering, raising $220.8 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses.</p> <p>The offering consisted of 13,800,000 shares of common stock priced at $16.00 per share, including 1,800,000 shares issued through the full exercise of the underwriters' overallotment option. All shares were offered by Apnimed. The stock began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol "APMD."</p> <p>BofA Securities, Evercore ISI, Cantor, and LifeSci Capital served as joint book-running managers for the offering.</p> <p>According to a press release, Apnimed http://www.streetinsider.com/Equity+Offerings/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html Mon, 03 Aug 2026 16:36:06 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537 http://www.streetinsider.com/Equity+Offerings/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html <p>Apnimed, Inc. (Nasdaq: APMD), a Cambridge, Massachusetts-based clinical-stage pharmaceutical company, closed its initial public offering, raising $220.8 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses.</p> <p>The offering consisted of 13,800,000 shares of common stock priced at $16.00 per share, including 1,800,000 shares issued through the full exercise of the underwriters' overallotment option. All shares were offered by Apnimed. The stock began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol "APMD."</p> <p>BofA Securities, Evercore ISI, Cantor, and LifeSci Capital served as joint book-running managers for the offering.</p> <p>According to a press release, Apnimed http://www.streetinsider.com/Equity+Offerings/Apnimed+raises+%24220.8M+in+upsized+Nasdaq+IPO/26858647.html Mon, 03 Aug 2026 16:36:06 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537 http://www.streetinsider.com/Press+Releases/Apnimed+Announces+Closing+of+Upsized+Initial+Public+Offering%2C+Including+Full+Exercise+of+Underwriters%E2%80%99+Option+to+Purchase+Additional+Shares/26858637.html <p>CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced the closing of its upsized initial public offering of an aggregate of 13,800,000 shares of its common stock, including the full exercise by the underwriters of their overallotment option to purchase 1,800,000 additional shares, at an initial public offering price of $16.00 per share. All of the shares of common stock were offered by Apnimed. Apnimed’s common stock http://www.streetinsider.com/Press+Releases/Apnimed+Announces+Closing+of+Upsized+Initial+Public+Offering%2C+Including+Full+Exercise+of+Underwriters%E2%80%99+Option+to+Purchase+Additional+Shares/26858637.html Mon, 03 Aug 2026 16:35:00 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537 http://www.streetinsider.com/Press+Releases/Apnimed+Announces+Closing+of+Upsized+Initial+Public+Offering%2C+Including+Full+Exercise+of+Underwriters%E2%80%99+Option+to+Purchase+Additional+Shares/26858637.html <p>CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced the closing of its upsized initial public offering of an aggregate of 13,800,000 shares of its common stock, including the full exercise by the underwriters of their overallotment option to purchase 1,800,000 additional shares, at an initial public offering price of $16.00 per share. All of the shares of common stock were offered by Apnimed. Apnimed’s common stock http://www.streetinsider.com/Press+Releases/Apnimed+Announces+Closing+of+Upsized+Initial+Public+Offering%2C+Including+Full+Exercise+of+Underwriters%E2%80%99+Option+to+Purchase+Additional+Shares/26858637.html Mon, 03 Aug 2026 16:35:00 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537 http://www.streetinsider.com/Press+Releases/Apnimed+Announces+Closing+of+Upsized+Initial+Public+Offering%2C+Including+Full+Exercise+of+Underwriters%E2%80%99+Option+to+Purchase+Additional+Shares/26858637.html <p>CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced the closing of its upsized initial public offering of an aggregate of 13,800,000 shares of its common stock, including the full exercise by the underwriters of their overallotment option to purchase 1,800,000 additional shares, at an initial public offering price of $16.00 per share. All of the shares of common stock were offered by Apnimed. Apnimed’s common stock http://www.streetinsider.com/Press+Releases/Apnimed+Announces+Closing+of+Upsized+Initial+Public+Offering%2C+Including+Full+Exercise+of+Underwriters%E2%80%99+Option+to+Purchase+Additional+Shares/26858637.html Mon, 03 Aug 2026 16:35:00 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537 http://www.streetinsider.com/Press+Releases/Apnimed+Announces+Closing+of+Upsized+Initial+Public+Offering%2C+Including+Full+Exercise+of+Underwriters%E2%80%99+Option+to+Purchase+Additional+Shares/26858637.html <p>CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced the closing of its upsized initial public offering of an aggregate of 13,800,000 shares of its common stock, including the full exercise by the underwriters of their overallotment option to purchase 1,800,000 additional shares, at an initial public offering price of $16.00 per share. All of the shares of common stock were offered by Apnimed. Apnimed’s common stock http://www.streetinsider.com/Press+Releases/Apnimed+Announces+Closing+of+Upsized+Initial+Public+Offering%2C+Including+Full+Exercise+of+Underwriters%E2%80%99+Option+to+Purchase+Additional+Shares/26858637.html Mon, 03 Aug 2026 16:35:00 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537 http://www.streetinsider.com/Press+Releases/Apnimed+Announces+Closing+of+Upsized+Initial+Public+Offering%2C+Including+Full+Exercise+of+Underwriters%E2%80%99+Option+to+Purchase+Additional+Shares/26858637.html <p>CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced the closing of its upsized initial public offering of an aggregate of 13,800,000 shares of its common stock, including the full exercise by the underwriters of their overallotment option to purchase 1,800,000 additional shares, at an initial public offering price of $16.00 per share. All of the shares of common stock were offered by Apnimed. Apnimed’s common stock http://www.streetinsider.com/Press+Releases/Apnimed+Announces+Closing+of+Upsized+Initial+Public+Offering%2C+Including+Full+Exercise+of+Underwriters%E2%80%99+Option+to+Purchase+Additional+Shares/26858637.html Mon, 03 Aug 2026 16:35:00 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537 http://www.streetinsider.com/Press+Releases/Apnimed+Announces+Closing+of+Upsized+Initial+Public+Offering%2C+Including+Full+Exercise+of+Underwriters%E2%80%99+Option+to+Purchase+Additional+Shares/26858637.html <p>CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced the closing of its upsized initial public offering of an aggregate of 13,800,000 shares of its common stock, including the full exercise by the underwriters of their overallotment option to purchase 1,800,000 additional shares, at an initial public offering price of $16.00 per share. All of the shares of common stock were offered by Apnimed. Apnimed’s common stock http://www.streetinsider.com/Press+Releases/Apnimed+Announces+Closing+of+Upsized+Initial+Public+Offering%2C+Including+Full+Exercise+of+Underwriters%E2%80%99+Option+to+Purchase+Additional+Shares/26858637.html Mon, 03 Aug 2026 16:35:00 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537 http://www.streetinsider.com/Press+Releases/Apnimed+Announces+Closing+of+Upsized+Initial+Public+Offering%2C+Including+Full+Exercise+of+Underwriters%E2%80%99+Option+to+Purchase+Additional+Shares/26858637.html <p>CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced the closing of its upsized initial public offering of an aggregate of 13,800,000 shares of its common stock, including the full exercise by the underwriters of their overallotment option to purchase 1,800,000 additional shares, at an initial public offering price of $16.00 per share. All of the shares of common stock were offered by Apnimed. Apnimed’s common stock http://www.streetinsider.com/Press+Releases/Apnimed+Announces+Closing+of+Upsized+Initial+Public+Offering%2C+Including+Full+Exercise+of+Underwriters%E2%80%99+Option+to+Purchase+Additional+Shares/26858637.html Mon, 03 Aug 2026 16:35:00 -0400 A.14860339 A.50202048 A.50213503 A.50214655 APMD O.10869727 O.32241120 O.50304126 O.51342537